• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

剂量调整:危重症患者抗生素治疗的新概念?

Dose modulation: a new concept of antibiotic therapy in the critically ill patient?

机构信息

Polyvalent Intensive Care Unit, São Francisco Xavier Hospital, CHLO, Estrada do Forte do Alto do Duque, 1449-005 Lisboa, Portugal.

出版信息

J Crit Care. 2013 Aug;28(4):341-6. doi: 10.1016/j.jcrc.2012.11.018. Epub 2013 Jan 18.

DOI:10.1016/j.jcrc.2012.11.018
PMID:23337485
Abstract

Considerable evidence has shown that adequate antibiotic therapy is of utmost importance in the critically ill septic patient. However, antibiotic concentration may be insufficient early in infection course. We propose the concept of dose modulation, meaning front-line variability of antibiotic dose, according to patient and microorganism characteristics, followed by its reduction after clinical response and patient recovery. Therefore, dose modulation means concentrating the largest weight of antibiotics at the front-end, when the microbial load is higher and the pharmacokinetic changes poses the highest risk of underdosing and nibbling off antibiotic dose, when the sepsis syndrome is improving, guided by pharmacokinetic and pharmacodynamic data.

摘要

大量证据表明,在重症感染性休克患者中,充分的抗生素治疗至关重要。然而,在感染早期,抗生素浓度可能不足。我们提出了剂量调整的概念,即根据患者和微生物特征,对一线抗生素剂量进行调整,然后在临床反应和患者康复后减少剂量。因此,剂量调整意味着在微生物负荷较高、药代动力学变化导致剂量不足风险最高的前端集中使用最大剂量的抗生素,然后根据药代动力学和药效学数据,在感染性休克综合征改善时减少剂量。

相似文献

1
Dose modulation: a new concept of antibiotic therapy in the critically ill patient?剂量调整:危重症患者抗生素治疗的新概念?
J Crit Care. 2013 Aug;28(4):341-6. doi: 10.1016/j.jcrc.2012.11.018. Epub 2013 Jan 18.
2
[Antibiotic strategies in the treatment of infection in critically ill patients].[危重症患者感染治疗中的抗生素策略]
Ugeskr Laeger. 2007 Feb 19;169(8):699-702.
3
Aminoglycosides in the intensive care unit: an old drug in a dynamic environment.重症监护病房中的氨基糖苷类药物:动态环境中的一种老药。
New Horiz. 1993 May;1(2):172-80.
4
A new paradigm for treating infections: "go hard and go home".一种治疗感染的新范式:“积极治疗,早日回家”。
Crit Care Resusc. 2009 Dec;11(4):276-81.
5
Pharmacokinetic issues for antibiotics in the critically ill patient.危重症患者使用抗生素的药代动力学问题。
Crit Care Med. 2009 Mar;37(3):840-51; quiz 859. doi: 10.1097/CCM.0b013e3181961bff.
6
[Sepsis in the critically-ill patient].[危重症患者的脓毒症]
Ugeskr Laeger. 2007 Feb 19;169(8):703-5.
7
[Adequate antibiotic therapy in intensive care units].[重症监护病房中的充分抗生素治疗]
Med Klin Intensivmed Notfmed. 2014 Apr;109(3):154-5. doi: 10.1007/s00063-013-0301-8.
8
[C-reactive protein concentrations during initial (empiric) treatment of neonatal sepsis].新生儿败血症初始(经验性)治疗期间的C反应蛋白浓度
Srp Arh Celok Lek. 2001 May-Jun;129 Suppl 1:17-22.
9
Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections.替加环素在患有严重医院获得性腹腔内感染的重症患者中的应用。
Rev Esp Quimioter. 2013 Mar;26(1):56-63.
10
Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?哌拉西林在脓毒症重症患者组织中的渗透——静脉推注与持续给药对比?
Crit Care Med. 2009 Mar;37(3):926-33. doi: 10.1097/CCM.0b013e3181968e44.

引用本文的文献

1
Artificial Intelligence to Close the Gap between Pharmacokinetic/Pharmacodynamic Targets and Clinical Outcomes in Critically Ill Patients: A Narrative Review on Beta Lactams.人工智能缩小重症患者药代动力学/药效学靶点与临床结局之间的差距:关于β-内酰胺类药物的叙述性综述
Antibiotics (Basel). 2024 Sep 6;13(9):853. doi: 10.3390/antibiotics13090853.
2
Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time.优化β-内酰胺类抗生素在临床实践中的应用:时间的检验
Open Forum Infect Dis. 2023 Jun 6;10(7):ofad305. doi: 10.1093/ofid/ofad305. eCollection 2023 Jul.
3
β-Lactam Dosing in Critical Patients: A Narrative Review of Optimal Efficacy and the Prevention of Resistance and Toxicity.
重症患者的β-内酰胺类药物给药:关于最佳疗效以及预防耐药性和毒性的叙述性综述
Antibiotics (Basel). 2022 Dec 18;11(12):1839. doi: 10.3390/antibiotics11121839.
4
Optimizing Antimicrobial Drug Dosing in Critically Ill Patients.优化重症患者的抗菌药物给药方案
Microorganisms. 2021 Jun 28;9(7):1401. doi: 10.3390/microorganisms9071401.
5
Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR).β-内酰胺类抗生素在危重症患者中的治疗优化:法国药理学和治疗学学会(Société Française de Pharmacologie et Thérapeutique-SFPT)和法国麻醉与重症监护医学学会(Société Française d'Anesthésie et Réanimation-SFAR)的指南。
Crit Care. 2019 Mar 29;23(1):104. doi: 10.1186/s13054-019-2378-9.
6
Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedure.迈向负责任使用抗生素的全球定义:一项国际多学科共识程序的结果。
J Antimicrob Chemother. 2018 Jun 1;73(suppl_6):vi3-vi16. doi: 10.1093/jac/dky114.
7
Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.危重症患者中哌拉西林浓度与治疗范围的关系——一项前瞻性观察性研究。
Crit Care. 2016 Apr 4;20:79. doi: 10.1186/s13054-016-1255-z.
8
Meropenem therapy in extracorporeal membrane oxygenation patients: an ongoing pharmacokinetic challenge.美罗培南在体外膜肺氧合患者中的治疗:一个持续存在的药代动力学挑战。
Crit Care. 2015 Jun 22;19(1):263. doi: 10.1186/s13054-015-0953-2.
9
Antibiotics and extracorporeal circulation--one size does not fit all.抗生素与体外循环——并非一概而论。
Crit Care. 2014 Dec 19;18(6):695. doi: 10.1186/s13054-014-0695-6.
10
Antibiotic dosing in the critically ill: asking the same questions but expecting different answers.危重症患者的抗生素给药:提出相同问题却期待不同答案。
Intensive Care Med. 2014 Nov;40(11):1780-2. doi: 10.1007/s00134-014-3477-3. Epub 2014 Sep 23.